AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06018896
Drug: Ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients with baseline serum Vitamin C concentration \< 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
Trial: NCT05461261
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.
Trial: NCT05461261
Drug: Platinum-based drugs
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
Trial: NCT06341621
Drug: 3-year abemaciclib without chemo
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
Trial: NCT04920968
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).
Trial: NCT04920968
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
Trial: NCT06265272
Drug: Injection of a gadolinium contrast agen
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~* About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~* After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;
Trial: NCT05104567
Drug: THOR-707
RxNorm normalized name: IL-2 variant THOR-707
DrugBank: Pegenzileukin (DB17495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion: intravenous infusion
Trial: NCT05104567
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for infusion: intravenous infusion
Trial: NCT05104567
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for infusion: intravenous infusion
Trial: NCT05884463
Drug: 18F-FAPI
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 18F-FAPI.
Trial: NCT05884463
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 18F-FDG.
Trial: NCT06144736
Drug: Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
Trial: NCT06522555
Drug: polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2)~Induction therapy:~The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.
Trial: NCT06522555
Drug: zanubrutinib, rituximab and lenalidomide
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)~Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.
Trial: NCT06499233
Drug: Trimethoprim/Sulfamethoxazole
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).
Trial: NCT05254639
Drug: DONEPEZIL
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
Trial: NCT04946929
Drug: Ticagrelor Oral Tablet [Brilinta]
RxNorm normalized name: ticagrelor Oral Tablet [Brilinta]
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor, 2-3mg/kg, 12h, p.o.
Trial: NCT06014138
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
Trial: NCT06014138
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
Trial: NCT06463652
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
Trial: NCT04892693
Drug: Talazoparib Oral Capsule
RxNorm normalized name: talazoparib Oral Capsule
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
Trial: NCT05277675
Drug: Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
Trial: NCT05955001
Drug: Tadalafil 5mg / Placebo
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients after Holmium laser Enucleation of Prostate (HoLEP) will receive single daily dose of Tadalafil for 3 months and compared to Placebo
Trial: NCT06313086
Drug: DP303c
RxNorm normalized name: ADC DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT06313086
Drug: trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous injection
Trial: NCT05129137
Drug: nefopam hydrochloride 30mg X2
RxNorm normalized name: nefopam 30 MG
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nefopam hydrochloride 30mg X2
Trial: NCT05129137
Drug: paracetamol 500 mg X2
RxNorm normalized name: Soothanol X2
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paracetamol 500 mg X2
Trial: NCT05129137
Drug: Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
Trial: NCT04799548
Drug: Transcatheter Arterial Chemoembolization
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid.
Trial: NCT04799548
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
Trial: NCT04806906
Drug: CC-486
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
Trial: NCT06626152
Drug: Apo-levocarb
RxNorm normalized name: varenicline
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As above.
Trial: NCT04789291
Drug: BI 1595043
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).
Trial: NCT06370728
Drug: Orforglipron
RxNorm normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06370728
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05573477
Drug: ATB-1011
RxNorm normalized name: ATB-346
DrugBank: ATB-346 (DB15377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05573477
Drug: ATB-1012
RxNorm normalized name: ATB-346
DrugBank: ATB-346 (DB15377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05573477
Drug: ATB-1013
RxNorm normalized name: ATB-346
DrugBank: ATB-346 (DB15377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04724629
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg of indirect IL-6 inhibitor
Trial: NCT04351373
Drug: Fluorescein Sodium
RxNorm normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration 1 mg/kg initial dosing if insufficient additional doses of 1 mg/kg may be administered.
Trial: NCT05532072
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rapamycin plus Methylprednisolone
Trial: NCT05532072
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone Alone
Trial: NCT04718285
Drug: Montelukast Oral Tablet
RxNorm normalized name: montelukast Oral Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
Trial: NCT04718285
Drug: Montelukast plus Favicovir (Favipiravir)
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
Trial: NCT04718285
Drug: Favicovir (Standard Treatment)
RxNorm normalized name: Favilavir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
Trial: NCT05764538
Drug: DAOIB
RxNorm normalized name: Dapagliflozin and Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
Trial: NCT05019846
Drug: Triptorelin Embonate
RxNorm normalized name: Triptorelin embonate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single administration before SRT starting
Trial: NCT05019846
Drug: Bicalutamide 50 mg
RxNorm normalized name: bicalutamide 50 MG
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose each day, 7 days before LHRH until 10 days after LHRH administration
Trial: NCT06375616
Drug: Nafamostat Mesylate
RxNorm normalized name: mesylate
DrugBank: Nafamostat (DB12598)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: During RRT, a priming dose of 20 mg of nafamostat mesylate (NM) is administered before initiation of the procedure. Upon starting the machine, there is no loading dose, but a maintenance infusion rate of 25 mg/h of NM is maintained. NM is discontinued in the last half hour before the end of the RRT session.
Trial: NCT06375616
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During RRT, a priming dose of 50 mg of unfractionated heparin (UFH) is administered before initiation of the procedure. Upon starting the machine, a loading dose of 0.2 mg/kg of UFH is given, followed by a maintenance infusion rate of 0.1 mg/kg/h of UFH. The anticoagulant is discontinued in the last half hour before the end of the RRT session.
Trial: NCT06617247
Drug: Intervention1: Cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Os cuidadores randomizados para esta intervenção usarão CBD oral 300 mg (ou seja, 150 mg, duas vezes ao dia) por quatro semanas. A substância será fornecida gratuitamente pela empresa Ease Labs e será administrada em cápsulas para promover o cegamento. Esta posologia foi baseada no estudo, no qual o CBD nesta dosagem e forma de apresentação provou ser seguro e eficaz na redução de indicadores de burnout em profissionais de saúde da linha de frente da COVID-19. A segurança do uso do CBD também foi relatada em estudos anteriores conduzidos com humanos. Os efeitos colaterais do uso do CBD são raros, incluindo sintomas leves e toleráveis (por exemplo, tontura, sonolência, fadiga, letargia, náusea, dor de cabeça, febre e alterações sensoriais).
Trial: NCT05287308
Drug: epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
Trial: NCT05287308
Drug: pirarubicin
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
Trial: NCT05287308
Drug: albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
Trial: NCT05287308
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
Trial: NCT05287308
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 80\~100mg/m2, i.v., d1, q3w.
Trial: NCT04498325
Drug: NT-I7
RxNorm normalized name: NT-I7
DrugBank: Efineptakin alfa (DB16395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied by study
Trial: NCT04936854
Drug: Sirolimus 1 mg Oral Tablet
RxNorm normalized name: SIROLIMUS 1 mg ORAL TABLET
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
Trial: NCT04936854
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.
Trial: NCT05578950
Drug: itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
Trial: NCT05578950
Drug: terbinafine
RxNorm normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
Trial: NCT05571644
Drug: mFOLFOXIRI + Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
Trial: NCT05496959
Drug: Lutetium Lu-177 PNT2002
RxNorm normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu-177 (DB13982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05657990
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.
Trial: NCT04803422
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
Trial: NCT06649422
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.
Trial: NCT06648057
Drug: lenvatinib plus pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times):~* Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2)~* (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time).~* Additional tumor tissue samples will be collected only if possible, according to the following schedule:~If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens).
Trial: NCT04810494
Drug: 2% Lidocaine HCl topical solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.
Trial: NCT04810494
Drug: 0.9% Sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.
Trial: NCT04760041
Drug: Midazolam nebulized
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam nebulized
Trial: NCT04760041
Drug: Midazolam oral solution
RxNorm normalized name: midazolam Oral Solution
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam given oral
Trial: NCT05117554
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Syrup solution